Loading clinical trials...
Loading clinical trials...
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
PETHEMA Foundation
NCT07471789 · Acute Myeloblastic Leukaemia, Leukemia, T-Cell
NCT07203742 · Acute Lymphoblastic Leukemia, Childhood Acute Leukemia, and more
Hospital General de Albacete
Albacete
Hospital Universitario
Alicante
Hospital Puerta del Mar
Cadiz
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions